Aidence receives CE Mark for AI-based pulmonary nodule management
11 Sept 2018

Aidence receives CE Mark for AI-based pulmonary nodule management

Aidence, an Amsterdam-based medical AI company, has reached yet another significant milestone in the field of automated pulmonary nodule management. Its product, Veye Chest version 2, a class IIa medical device, has obtained the CE mark. Veye Chest is now cleared to detect and characterize lung nodules in CT images in clinical practice across the EU.

Imaging plays a central role in the diagnosis of lung cancer, which often presents as pulmonary nodules on chest CT scans. Detecting and characterizing these nodules can be a trying and time-consuming task for radiologists who are expected to report nodules as small as 5mm. As a result of their small size and resemblance to normal lung structures, detecting these pulmonary nodules is often time-consuming and susceptible to errors.

Veye Chest leverages the power of Artificial Intelligence to assist radiologists in the detection and reporting of pulmonary nodules. Meticulously co-designed by the brightest AI developers and radiologists, this AI assistant integrates seamlessly into the radiologists’ workflow. Veye Chest provides accurate, prompt and valuable nodule reports within radiologists’ existing workstations.

Building on the CE-marked software for the automated detection of pulmonary nodules, Veye Chest adds the first clinically approved features for fully automated nodule diameter and volume measurement, growth rate and composition. This first in radiology removes the need for time-consuming manual detection and quantification.

The novel features of Veye Chest differ from current computer aided detection systems in that they automate the entire process of nodule management. All aforementioned clinical parameters provided by Veye Chest are available instantly in a radiologists workstation upon the opening of a case. This empowers radiologists and other physicians to quickly determine the correct course of action for each detected nodule. The accuracy of the new features of fully automated nodule diameter & volume measurement, growth rate and composition have been validated in a clinical study at NHS Lothian and the University of Edinburgh.

Mark-Jan Harte, CEO of Aidence: “AI in the medical field has long been on the horizon and now, with this release, we are actually putting AI-powered software in the hands of doctors. I am very excited by the ability of Veye Chest to assist in the early detection of lung cancer while at the same time improving reading efficiency.”

Several hospitals in the Netherlands are currently testing Veye Chest. The process of upgrading these hospitals to the latest version will now commence. Hilversum and Blaricum based Tergooi and Dordrecht based Albert Schweitzer will be among the first hospitals to implement Veye Chest version 2 in September, with other hospitals following soon thereafter. If you would like to find out more about Aidence and Veye Chest please visit or contact us at